摘要
目的研究花脸蘑多糖(LSPb1)在体内对喉癌血管新生的作用,探究其抗肿瘤的作用机制。方法 ELISA检测体外培养的喉癌Hep-2细胞在低氧环境下分泌血管内皮生长因子(VEGF)的量;异种移植瘤模型研究LSPb1对移植瘤体积的影响;ELISA和RT-PCR检测移植瘤内VEGF蛋白和mRNA水平的表达;免疫组化定量分析移植瘤组织中新生血管的数量。结果在Hep-2细胞中,LSPb1显著抑制了VEGF的分泌(P<0.001)。在Hep-2异种移植瘤模型荷瘤裸鼠中发现LSPb1显著抑制了瘤体的生长(P<0.05);与对照组相比,LSPb1处理移植瘤中VEGF mRNA水平无表达,VEGF因子的表达下降(P<0.01),血管密度显著下降(P<0.01)。结论 LSPb1作为一个潜在的喉癌治疗药物有望在治疗人喉癌中发挥重要的作用。
Objective To study Lepista sordida polysaccharides( LSPb1) for laryngeal cancer angiogenesis in vivo,and explore its anti-tumor mechanism. Methods ELISA was used to detect the vascular endothelial growth factor( VEGF) secreting by laryngeal cancer Hep-2 cells.The effect of LSPb1 in vivo laryngeal cancer Hep-2 cells in xenograft tumor volume was studied.ELISA and RT-PCR were used to detect the expression of VEGF in the tumor protein and mRNA levels. Immunohistochemical method was used to quantitatively analyse tumor tissue angiogenesis number. Results In Hep-2 cells,LSPb1 significantly inhibited the secretion of VEGF( P 0. 001). LSPb1 also significantly inhibited Hep-2 xenograft tumor growth in nude mice( P 0. 05). Compared with the control,the expression of VEGF mRNA was negative,the secretion of VEGF was reduced( P 0. 05),and the density of blood vessels was decreased within the tumor tissue in nude mice treated with LSPb1( P 0. 01). Conclusion LSPb1 larynx as a potential therapeutic agent is expected to play an important role in the treatment of human laryngeal carcinoma.
出处
《哈尔滨医科大学学报》
CAS
2015年第1期34-37,共4页
Journal of Harbin Medical University